2022 BIO CEO & Investor Conference
Presentation
2022 BIO CEO & Investor Conference Read More »
Webcast 3 2021 Quarterly Results PDF Release AUDIO Webcast PDF HTML 10-Q Filing ZIP XLS HTML XBRL
Third Quarter 2021 Operational Highlights and Financial Results Conference Call Read More »
Initiated a Phase 1 Multiple Ascending Dose Clinical Trial of SYN-020 in Healthy Adult Volunteers; Topline Data Readout Expected in Q2 2022 Enrollment Remains Ongoing in Phase 1b/2a Clinical Trial of SYN-004 in Allogeneic HCT Recipients Reports $72.1 Million of Cash on Hand to Fund Clinical Programs Through Key Milestones Beyond 2022 ROCKVILLE, Md., Nov.
Webcast The archived replay of the call will be available for approximately ninety (90) days, beginning approximately one hour after the call’s conclusion. 2 2021 Quarterly Results PDF Release AUDIO Webcast PDF HTML 10-Q Filing ZIP XLS HTML XBRL
Second Quarter 2021 Operational Highlights and Financial Results Conference Call Read More »
Phase 1 Single-Ascending Dose Clinical Trial of SYN-020 Demonstrated Favorable Safety Profile and was Well Tolerated at All Dose Levels; A Second Phase 1 Multiple-Ascending Dose Clinical Trial Expected to Commence in Q3 2021 Enrollment in Phase 1b/2a Clinical Trial of SYN-004 in Allogeneic HCT Recipients Proceeding as Planned Reports $74.3 Million of Cash on
Updated Agreement Includes Intellectual Property and Technology for Use of SYN-020 Intestinal Alkaline Phosphatase to Inhibit Liver Fibrosis in Select Diseases, Including Nonalcoholic Fatty Liver Disease ROCKVILLE, Md., August 3, 2021 /PRNewswire/ — Synthetic Biologics, Inc. (NYSE American: SYN), a diversified clinical-stage company leveraging the microbiome to develop therapeutics designed to prevent and treat gastrointestinal (“GI”) diseases in
Orally Administered SYN-020 Observed to be Well Tolerated in Healthy Volunteers; A Second Phase 1 Multiple-Ascending Dose Study is on Track to Begin in Q3 2021 ROCKVILLE, Md., June 29, 2021 /PRNewswire/ — Synthetic Biologics, Inc. (NYSE American: SYN), a diversified clinical-stage company leveraging the microbiome to develop therapeutics designed to prevent and treat gastrointestinal (GI) diseases in areas
Webcast 1 2021 Quarterly Results PDF Release AUDIO Webcast PDF HTML 10-Q Filing ZIP XLS HTML XBRL
First Quarter 2021 Operational Highlights and Financial Results Conference Call Read More »
ROCKVILLE, Md., April 14, 2021 /PRNewswire/ — Synthetic Biologics, Inc. (NYSE American: SYN), a diversified clinical-stage company leveraging the microbiome to develop therapeutics designed to prevent and treat gastrointestinal (GI) diseases in areas of high unmet need, today announced enrollment has commenced and the first patient has been dosed in its Phase 1b/2a clinical trial of SYN-004 (ribaxamase) in
Webcast 4 2020 Quarterly Results PDF Release AUDIO Webcast PDF HTML 10-K Filing ZIP XLS HTML XBRL
Fourth Quarter 2020 Operational Highlights and Financial Results Conference Call Read More »